MedTrace Logo

Low-dose S-ketamine in Women With Prenatal Depression

NCT04414943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 364

Last updated 2023-04-04

No results posted yet for this study

Summary

Prenatal depression is an important risk factor of postpartum depression. Low-dose ketamine has been used for depression treatment. As a stereoisomer of ketamine, s-ketamine has similar effects to ketamine in anti-depression. We speculate that, for pregnant women with prenatal depression, low-dose s-ketamine infusion after childbirth may reduce the incidence of postpartum depression.

Conditions

Interventions

DRUG

S-ketamine

For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.

DRUG

Placebo

For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.

Sponsors & Collaborators

  • Peking University International Hospital

    collaborator OTHER

  • Hunan Provincial Maternal and Child Health Care Hospital

    collaborator OTHER

  • Nanjing Medical University

    collaborator OTHER

  • Women's Hospital School Of Medicine Zhejiang University

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Dong-Xin Wang, MD, PhD · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-19
Primary Completion
2022-08-03
Completion
2022-08-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414943 on ClinicalTrials.gov